United Capital Financial Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

United Capital Financial Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-216	Closed	-$161K	–	1376
2017 Q4	$161K	Hold	216	–	–	﹤0.01%	1255
2017 Q3	$62K	Hold	216	–	–	﹤0.01%	1288
2017 Q2	$55K	Hold	216	–	–	﹤0.01%	1260
2017 Q1	$72K	Hold	216	–	–	﹤0.01%	1222
2016 Q4	$130K	Hold	216	–	–	﹤0.01%	1220
2016 Q3	$245K	Hold	216	–	–	﹤0.01%	1127
2016 Q2	$259K	Buy	+216	New	+$271K	﹤0.01%	1086

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

United Capital Financial Advisors's NBSE Position: Q1 2018 in Review

United Capital Financial Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 216 shares — an estimated $161K sold.

United Capital Financial Advisors first reported a position in NBSE in Q2 2016 and held it in 7 quarters. The position peaked at $259K in Q2 2016. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

United Capital Financial Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
United Capital Financial Advisors sold 216 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $161K.
United Capital Financial Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
United Capital Financial Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $259K in Q2 2016.
35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on United Capital Financial Advisors's 13F filing for Q1 2018, filed 15 May 2018.